latest update:
[TrialBase DB]

trial summary · NCT07213960

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of APL2 in Adults and Adolescents With Focal Segmental Glomerulosclerosis

Trial record from the TrialBase DB dataset, status RECRUITING, condition FSGS, sponsored by Apellis Pharmaceuticals, Inc.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07213960phase PHASE2/PHASE3enrollment 270start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This is a sequential phase 2/3 study to evaluate the efficacy and safety of twice-weekly subcutaneous (SC) infusions of APL2 in patients diagnosed with FSGS. The initial phase 2 portion is a single-arm, open-label study in adults diagnosed with FSGS. Phase 2 will commence prior to randomizing for phase 3. The phase 3 portion of the study is a randomized, placebo-controlled, double-blinded, multicenter study in adults and adolescents diagnosed with FSGS.

Source record: https://clinicaltrials.gov/study/NCT07213960

Facts

registry idNCT07213960
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2/PHASE3
study typeINTERVENTIONAL
lead conditionFSGS
sponsorApellis Pharmaceuticals, Inc.
sponsor classINDUSTRY
enrollment270
start date2026-12
primary completion2029-10
completion2029-12
results postednot reported

Conditions

  • FSGS

Interventions

  • APL2
  • Placebo

Countries

  • United States

Intervention types: DRUG, OTHER

Work with this record